Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Capital Expenditures: 2011-2024

Historic Capital Expenditures for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $6.5 million.

  • Ptc Therapeutics' Capital Expenditures rose 559.96% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 23.52%. This contributed to the annual value of $6.5 million for FY2024, which is 77.14% down from last year.
  • As of FY2024, Ptc Therapeutics' Capital Expenditures stood at $6.5 million, which was down 77.14% from $28.4 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Capital Expenditures ranged from a high of $32.0 million in FY2022 and a low of $6.5 million during FY2024.
  • In the last 3 years, Ptc Therapeutics' Capital Expenditures had a median value of $28.4 million in 2023 and averaged $22.3 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 58.12% in 2021, then crashed by 77.14% in 2024.
  • Ptc Therapeutics' Capital Expenditures (Yearly) stood at $17.8 million in 2020, then skyrocketed by 58.12% to $28.2 million in 2021, then rose by 13.48% to $32.0 million in 2022, then declined by 11.18% to $28.4 million in 2023, then tumbled by 77.14% to $6.5 million in 2024.